Deudomperidone (developmental code name CIN-102; also known as deuterated domperidone) is a dopamine antagonist medication which is under development in the United States for the treatment of gastroparesis.[1][2][3] It acts as a selective dopamine D2 and D3 receptor antagonist and has peripheral selectivity.[2][3] Deudomperidone is a deuterated form of domperidone, and it is suggested that deudomperidone may have improved efficacy, tolerability, and pharmacokinetics compared to domperidone.[2][3] As of January 2022, deudomperidone is in phase 2 clinical trials for the treatment of gastroparesis.[1]

See also

References

  1. ^ a b "Deudomperidone - CinRx Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ^ a b c Heckroth M, Luckett RT, Moser C, Parajuli D, Abell TL (April 2021). "Nausea and Vomiting in 2021: A Comprehensive Update". Journal of Clinical Gastroenterology. 55 (4): 279–299. doi:10.1097/MCG.0000000000001485. PMC 7933092. PMID 33471485.
  3. ^ a b c Wo JM, McCallum RW, Gonzalez Z (2021). "Antiemetic therapy for gastroparesis". In McCallum RW, Parkman HP (eds.). Gastroparesis. Elsevier. pp. 341–359. doi:10.1016/B978-0-12-818586-5.00025-9. ISBN 9780128185865. S2CID 225132800.

External links